{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:26:15Z","timestamp":1787966775426,"version":"build-2784847793"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/SKK08\/USM\/02\/6"],"award-info":[{"award-number":["FRGS\/1\/2018\/SKK08\/USM\/02\/6"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Thalassemias are monogenic hematologic diseases that are classified as \u03b1- or \u03b2-thalassemia according to its quantitative abnormalities of adult \u03b1- or \u03b2-globin chains. \u03b2-thalassemia has widely spread throughout the world especially in Mediterranean countries, the Middle East, Central Asia, India, Southern China, and the Far East as well as countries along the north coast of Africa and in South America. The one and the only cure for \u03b2-thalassemia is allogenic hematopoietic stem cell transplantations (HSCT). Nevertheless, the difficulty to find matched donors has hindered the availability of this therapeutic option. Therefore, this present review explored the alternatives for \u03b2-thalassemia treatment such as RNA manipulation therapy, splice-switching, genome editing and generation of corrected induced pluripotent stem cells (iPSCs). Manipulation of \u03b2-globin RNA is mediated by antisense oligonucleotides (ASOs) or splice-switching oligonucleotides (SSOs), which redirect pre-mRNA splicing to significantly restore correct \u03b2-globin pre-mRNA splicing and gene product in cultured erythropoietic cells. Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)\/CRISPR-associated 9 (Cas9) are designer proteins that can alter the genome precisely by creating specific DNA double-strand breaks. The treatment of \u03b2-thalassemia patient-derived iPSCs with TALENs have been found to correct the \u03b2-globin gene mutations, implying that TALENs could be used as a therapy option for \u03b2-thalassemia. Additionally, CRISPR technologies using Cas9 have been used to fix mutations in the \u03b2-globin gene in cultured cells as well as induction of hereditary persistence of fetal hemoglobin (HPFH), and \u03b1-globin gene deletions have proposed a possible therapeutic option for \u03b2-thalassemia. Overall, the accumulated research evidence demonstrated the potential of ASOs-mediated aberrant splicing correction of \u03b2-thalassemia mutations and the advancements of genome therapy approaches using ZFNs, TALENs, and CRISPR\/Cas9 that provided insights in finding the permanent cure of \u03b2-thalassemia.<\/jats:p>","DOI":"10.3389\/fped.2022.901605","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T06:20:43Z","timestamp":1655274043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Genetic Manipulation Strategies for \u03b2-Thalassemia: A Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Nur Atikah","family":"Zakaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosnah","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Zaidah","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Aziz","family":"Mohamed Yusoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaharum","family":"Shamsuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridhwan","family":"Abdul Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Farid","family":"Johan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2010.05546.x","article-title":"Thalassemia as a global health problem: recent progress toward its control in the developing countries","volume":"1202","author":"Weatherall","year":"2010","journal-title":"Ann N Y Acad Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","article-title":"Beta-thalassemia","volume":"12","author":"Cao","year":"2010","journal-title":"Genet Med."},{"key":"B3","first-page":"328","article-title":"Iron overload in beta thalassaemia major and intermedia patients","volume":"8","author":"Mishra","year":"2013","journal-title":"Maedica (Bucur)."},{"key":"B4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1179\/1607845413Y.0000000120","volume":"19","author":"Matta","year":"2014","journal-title":"Hematology."},{"key":"B5","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica."},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"2","author":"Zurlo","year":"1989","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-018-2411-9","volume":"108","author":"Asadov","year":"2018","journal-title":"Int J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"a011726","DOI":"10.1101\/cshperspect.a011726","article-title":"Pathophysiology and clinical manifestations of the \u03b2-thalassemias","volume":"2","author":"Nienhuis","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.21037\/tp-20-415","article-title":"Hematopoietic stem cell transplantation for thalassemia major using hla fully-matched and mismatched donor grafts","volume":"10","author":"Huang","year":"2021","journal-title":"Transl Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0889-8588(05)70109-X","article-title":"Bone marrow transplantation for beta-thalassemia","volume":"13","author":"Giardini","year":"1999","journal-title":"Hematol\/Oncol Clin North America."},{"key":"B11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5455\/msm.2020.32.277-282","article-title":"Hematopoietic stem cell transplantation in thalassemia patients: a jordanian single centre experience","volume":"32","author":"Mustafa","year":"2020","journal-title":"Mater Sociomed."},{"key":"B12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood-2019-123440","article-title":"Clinical outcomes after allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent \u03b2-thalassemia treated at the bambino ges\u00f9 children's hospital, Rome, Italy","volume":"134","author":"Merli","year":"2019","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3324\/haematol.12732","article-title":"Towards the genetic treatment of \u03b2-thalassemia: new disease models, new vectors, new cells","volume":"93","author":"Moi","year":"2008","journal-title":"Haematologica."},{"key":"B14","doi-asserted-by":"publisher","first-page":"D1063","DOI":"10.1093\/nar\/gkt911","article-title":"Updates of the hbvar database of human hemoglobin variants and thalassemia mutations","volume":"42","author":"Giardine","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1006\/bcmd.2001.0430","article-title":"Rapid identification of hemoglobin variants by electrospray ionization mass spectrometry","volume":"27","author":"Wild","year":"2001","journal-title":"Blood Cells Mol Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"a011734","DOI":"10.1101\/cshperspect.a011734","article-title":"The hemoglobin e thalassemias","volume":"2","author":"Fucharoen","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"a011700","DOI":"10.1101\/cshperspect.a011700","article-title":"The molecular basis of \u03b2-thalassemia","volume":"3","author":"Thein","year":"2013","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B18","first-page":"522","article-title":"Hb E\/Beta-thalassaemia: a common & clinically diverse disorder","volume":"134","author":"Olivieri","year":"2011","journal-title":"Indian J Med Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.hoc.2010.08.008","article-title":"Hbe\/\u03b2-thalassemia: basis of marked clinical diversity","volume":"24","author":"Olivieri","year":"2010","journal-title":"Hematol Oncol Clin North Am."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2001-2-5-reviews1015","article-title":"Morpholino antisense oligonucleotides: tools for investigating vertebrate development","volume":"2","author":"Corey","year":"2001","journal-title":"Genome Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7672","DOI":"10.1038\/s41598-019-43964-3","article-title":"Restoration of correct \u03b2ivs2-654-globin MRNA splicing and hba production by engineered U7 snrna in \u03b2-thalassaemia\/Hbe erythroid cells","volume":"9","author":"Nualkaew","year":"2019","journal-title":"Sci Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1073\/pnas.97.17.9591","article-title":"Restoration of hemoglobin a synthesis in erythroid cells from peripheral blood of thalassemic patients","volume":"97","author":"Lacerra","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1124\/mol.62.3.545","article-title":"Restoration of human beta-globin gene expression in murine and human ivs2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides","volume":"62","author":"Suwanmanee","year":"2002","journal-title":"Mol Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1073\/pnas.0812436106","article-title":"Rna repair restores hemoglobin expression in ivs2\u2013654 thalassemic mice","volume":"106","author":"Svasti","year":"2009","journal-title":"Proc Nat Acad Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1006\/mthe.2002.0805","article-title":"Repair of a splicing defect in erythroid cells from patients with beta-Thalassemia\/Hbe Disorder","volume":"6","author":"Suwanmanee","year":"2002","journal-title":"Mol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MPH.0b013e3181639afe","article-title":"Correction of aberrant pre-mrna splicing by antisense oligonucleotides in beta-thalassemia egyptian patients with ivsi-110 mutation","volume":"30","author":"El-Beshlawy","year":"2008","journal-title":"J Pediatr Hematol Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3324\/haematol.2019.226852","article-title":"2'-O-Methoxyethyl splice-switching oligos correct splicing from ivs2-745 beta-thalassemia patient cells restoring hba production and chain rebalance","volume":"106","author":"Dong","year":"2019","journal-title":"Haematologica."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e3321","DOI":"10.1002\/jgm.3321","article-title":"U7 Snrna: a tool for gene therapy","volume":"23","author":"Gadgil","year":"2021","journal-title":"J Gene Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1182\/blood-2002-06-1869","article-title":"High-level expression of hemoglobin a in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snrna","volume":"101","author":"Vacek","year":"2003","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/sctm.16-0121","article-title":"Enhancement of \u03b2-globin gene expression in thalassemic ivs2-654 induced pluripotent stem cell-derived erythroid cells by modified u7 snrna","volume":"6","author":"Phanthong","year":"2017","journal-title":"Stem Cells Transl Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1089\/hum.2020.145","article-title":"Engineered U7 small nuclear Rna restores correct \u03b2-globin pre-mrna splicing in mouse \u03b2(Ivs2-654)-thalassemic erythroid progenitor cells","volume":"32","author":"d'Arqom","year":"2021","journal-title":"Human Gene Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbrc.2018.03.102","article-title":"Engineered U7 snrna mediates sustained splicing correction in erythroid cells from \u03b2-thalassemia\/Hbe patients","volume":"499","author":"Preedagasamzin","year":"2018","journal-title":"Biochem Biophys Res Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood.2019000949","article-title":"Lentiviral and genome-editing strategies for the treatment of \u03b2-hemoglobinopathies","volume":"134","author":"Magrin","year":"2019","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","article-title":"Ready for repair? Gene editing enters the clinic for the treatment of human disease","volume":"18","author":"Ernst","year":"2020","journal-title":"Molec Ther Methods Clin Develop."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban","year":"2015","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3408","article-title":"Homology-driven genome editing in hematopoietic stem and progenitor cells using zfn mrna and aav6 donors","volume":"33","author":"Wang","year":"2015","journal-title":"Nat Biotechnol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nbt.3513","article-title":"Targeted gene addition in human Cd34(+) hematopoietic cells for correction of x-linked chronic granulomatous disease","volume":"34","author":"De Ravin","year":"2016","journal-title":"Nat Biotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/bs.pmbts.2021.01.025","article-title":"Genome editing approaches to \u03b2-hemoglobinopathies","volume":"182","author":"Brusson","year":"2021","journal-title":"Prog Mol Biol Transl Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2019-125743","article-title":"Preliminary results of a phase 1\/2 clinical study of zinc finger nuclease-mediated editing of bcl11a in autologous hematopoietic stem cells for transfusion-dependent beta thalassemia","volume":"134","author":"Smith","year":"2019","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"34671","DOI":"10.1074\/jbc.M113.496174","article-title":"Transcription activator-like effector nuclease (talen)-mediated gene correction in integration-free \u03b2-thalassemia induced pluripotent stem cells","volume":"288","author":"Ma","year":"2013","journal-title":"J Biol Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.3324\/haematol.2018.215178","article-title":"Correction of Ivs I-110(G>a) \u03b2-thalassemia by crispr\/cas-and talen-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells","volume":"104","author":"Patsali","year":"2019","journal-title":"Haematologica."},{"key":"B43","doi-asserted-by":"publisher","first-page":"12065","DOI":"10.1038\/srep12065","article-title":"Liu X-z, Wang T-t, Cheng L, Wang B-y, et al. Both talens and crispr\/Cas9 directly target the Hbb Ivs2-654 (C > T) mutation in beta-thalassemia-derived Ipscs","volume":"5","author":"Xu","year":"2015","journal-title":"Sci Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e12491","DOI":"10.1111\/cpr.12491","article-title":"Treatment of \u03b2(654) -thalassaemia by talens in a mouse model","volume":"51","author":"Fang","year":"2018","journal-title":"Cell Prolif."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1089\/scd.2014.0347","article-title":"Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by Crispr\/Cas9 system","volume":"24","author":"Song","year":"2015","journal-title":"Stem Cells Dev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.1111\/jcmm.14669","article-title":"Efficient gene correction of an aberrant splice site in \u03b2-thalassaemia ipscs by crispr\/cas9 and single-strand oligodeoxynucleotides","volume":"23","author":"Xiong","year":"2019","journal-title":"J Cell Mol Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1182\/blood-2019-01-895094","article-title":"Editing aberrant splice sites efficiently restores \u03b2-globin expression in \u03b2-thalassemia","volume":"133","author":"Xu","year":"2019","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s13287-020-01876-4","article-title":"Crispr-mediated gene modification of hematopoietic stem cells with beta-thalassemia ivs-1-110 mutation","volume":"11","author":"Gabr","year":"2020","journal-title":"Stem Cell Res Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1101\/gr.173427.114","article-title":"Seamless gene correction of \u03b2-thalassemia mutations in patient-specific ipscs using crispr\/cas9 and piggybac","volume":"24","author":"Xie","year":"2014","journal-title":"Genome Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"577053","DOI":"10.3389\/fgene.2020.577053","article-title":"Transcriptome analyses of \u03b2-thalassemia \u221228(a>G) mutation using isogenic cell models generated by crispr\/cas9 and asymmetric single-stranded oligodeoxynucleotides (Assodns)","volume":"11","author":"Li","year":"2020","journal-title":"Front Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"16576","DOI":"10.1074\/jbc.M116.719237","article-title":"Combining single strand oligodeoxynucleotides and crispr\/cas9 to correct gene mutations in \u03b2-thalassemia-induced pluripotent stem cells","volume":"291","author":"Niu","year":"2016","journal-title":"J Biol Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2016.11.010","article-title":"One-step biallelic and scarless correction of a \u03b2-thalassemia mutation in patient-specific ipscs without drug selection","volume":"6","author":"Liu","year":"2017","journal-title":"Molec Ther Nucl Acids."},{"key":"B53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13287-018-0779-3","article-title":"One-step genetic correction of hemoglobin e\/beta-thalassemia patient-derived Ipscs by the Crispr\/Cas9 system","volume":"9","author":"Wattanapanitch","year":"2018","journal-title":"Stem Cell Res Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.omtm.2021.03.025","article-title":"Efficient crispr-cas9-based genome editing of \u03b2-globin gene on erythroid cells from homozygous \u03b2(0)39-thalassemia patients","volume":"21","author":"Cosenza","year":"2021","journal-title":"Molec Ther Methods Clin Develop."},{"key":"B55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/sctm.17-0066","article-title":"A universal approach to correct various Hbb gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease","volume":"7","author":"Cai","year":"2018","journal-title":"Stem Cells Transl Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1073\/pnas.1612075113","article-title":"Genome editing using crispr-cas9 to create the hpfh genotype in hspcs: an approach for treating sickle cell disease and \u03b2-thalassemia","volume":"113","author":"Ye","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2020001996","article-title":"Correction of \u03b2-thalassemia by crispr\/cas9 editing of the \u03b1-globin locus in human hematopoietic stem cells","volume":"5","author":"Pavani","year":"2021","journal-title":"Blood advances."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.ymthe.2018.06.002","article-title":"Global transcriptional response to crispr\/cas9-aav6-based genome editing in Cd34+ hematopoietic stem and progenitor cells","volume":"26","author":"Cromer","year":"2018","journal-title":"Molecular Therapy."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.901605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T06:20:49Z","timestamp":1655274049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.901605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":58,"alternative-id":["10.3389\/fped.2022.901605"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.901605","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"901605"}}